期刊文献+

乌司他丁对内镜逆行胰胆管造影术后高淀粉酶血症及急性胰腺炎的预防作用 被引量:3

Preventive effects of ulinastatin on post ERCP hyperamylasemia and acute pancreatitis
下载PDF
导出
摘要 目的探讨乌司他丁对内镜逆行胰胆管造影(ERCP)术后高淀粉酶血症及急性胰腺炎的预防作用。方法将40例患者随机分为乌司他丁组和对照组。乌司他丁组造影前1h静滴乌司他丁2×105U,对照组静滴生理盐水250mL,观察术前和术后6h及24h血清淀粉酶的变化。结果乌司他丁组有3例和对照组有10例发生高淀粉酶血症,两组差异有统计学意义(P<0.05);乌司他丁组没有发生急性胰腺炎病例,对照组有2例发生急性胰腺炎,两组差异有统计学意义(P<0.05)。结论乌司他丁能有效地预防ERCP术后因胰管造影所致的高淀粉酶血症及急性胰腺炎。 Objective To investigate the preventive effects of ulinastatin on post endoscopic retrograde cholangiopancreatography(ERCP) hyperamylasemia and acute pancreatitis. Methods Forty patients were divided into 2' groups randomly, and ulinastatin of 2×10^5U was given to group A(n=20) by i.v. 1 h before ERCP while saline of 250 mL was given to group B(n=20) as control. Serum amylase was measured before ERCP, 6 h and 24 h after ERCP. Results Post ERCP hyperamylasemia occurred in 3 patients from group A(15%) and 10 from group B(50%), and there was a significant difference between these two groups(P〈0.05). Two cases from group B were suffered from acute pancreatitis(10%), but no cases from group A were suffered from it. The difference was also significant(P〈0.05). Conclusion Ulinastatin can effectively prevent post ERCP hyperamylasemia and acute pancreatitis.
出处 《兰州大学学报(医学版)》 CAS 2005年第3期24-25,40,共3页 Journal of Lanzhou University(Medical Sciences)
  • 相关文献

参考文献4

二级参考文献3

共引文献137

同被引文献30

  • 1陈兴田,费志勇,沈玉法,彭文洪,王瑞武.乌司他丁预防ERCP术后急性胰腺炎临床观察[J].山东医药,2005,45(4):44-45. 被引量:3
  • 2COOPER ST, SLIVKA A. Incidence, risk factors, and prevention of post-ERCP pancreatitis[J]. Gastroenterol Clin North Am, 2007, 36(2): 259-276.
  • 3CHENG CL, SHERMAN S, WATKINS JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study [J]. Am J Gastroenterol, 2006, 101(1): 139-147.
  • 4FREEMAN ML, DISARIO JA, NELSON DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, muhicenter study[J]. Gastrointest Endosc, 2001(54): 425-434.
  • 5ARONSON N, FLAMM CR, BOHN RL, et al. Evidence-based assessment: lbatient, procedure, or operator factors associated with ERCP complications[J]. Gastrointest Endosc, 2002(56):S294-302.
  • 6YO0 KS, HUH KR, KIM YJ, et al. Nafamostat mesilate for pre- vention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled triM[J]. Pancreas, 2011, 40(2): 181-186.
  • 7CHOI CW, KANG DH, KIM GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis [J]. Gastrointest Endosc, 2009, 69 (4): e11-18.
  • 8YOO JW, RYU JK, LEE SH, et al. Preventive effects of ulinas- tatin on post-endoscopic retrograde on pan- place- creatitis in high-risk patients: a prospective, randomized, bo-controlled trial[J]. Pancreas, 2008, 37(4): 366-370.
  • 9MANES G, ARDIZZONE S, LOMBARDI G, et al. Efficacy of postprocedure administration of gabexate mesylate in the preven- tion of post-ERCP pancreatitis: a randomized, controlled, multi- center study[J]. Gastrointest Endosc, 2007, 65(7): 982-987.
  • 10XIONG GS, WU SM, ZHANG XW, et al. Clinical trim of gabexate in the prophylaxis of post-endoscopic retrograde cholan- giopancreatography pancreatitis[J]. Braz J Med Biol Res, 2006, 39 (1): 85-90.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部